RemeGen's Telitacicept (RC18) Received Orphan Drug Designation From EMA for Myasthenia Gravis

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis

/PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has...

RemeGen's Telitacicept Approved for Treatment of Myasthenia Gravis in China

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.

Joburg Woman Walks 35 Days to Cape Town, Raising Rare Disease Awareness for Her Husband – Patient Worthy

In an inspiring act of love and advocacy, Joburg resident Nthabiseng Mokoena has completed a remarkable 35-day walk from Johannesburg to Cape Town to raise awareness for a rare disease that affects her husband. As reported by TimesLIVE, Nthabiseng embarked on the grueling journey to shine a spotlight on myasthenia gravis, a little-known autoimmune condition […]

Breakthrough: RemeGen's MG Drug Achieves 98% Efficacy and Rare EMA-FDA Dual Orphan Status

First-ever dual-target biologic for Myasthenia Gravis scores both EMA and FDA orphan designations. Phase III shows 98% efficacy rate. See global market potential.

Myasthenia gravis market across 7MM set to grow at 5.3% CAGR between 2024 and 2034, forecasts GlobalData - Express Pharma

The myasthenia gravis (MG) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is poised to grow at a compound annual growth rate (CAGR) of 5.3 per cent from $6.1 billion in 2024 to $10.3 billion in 2034, forecasts GlobalData. GlobalData’s report, “Myasthenia Gravis – Opportunity Assessment and Forecast,” reveals that growth will primarily be driven by an increase in diagnosed prevalence as well …

Myasthenia gravis market across 7MM set to grow at 5.3% CAGR between 2024 and 2034, forecasts GlobalData

The myasthenia gravis (MG) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is poised to grow at a compound annual growth rate (CAGR) of 5.3% from $6.1 billion in 2024 to $10.3 billion in 2034, forecasts GlobalData, a leading data and analytics company. GlobalData’s report, “Myasthenia Gravis – Opportunity Assessment and Forecast,” reveals that growth will primarily be driven by an increase in…